explore -WSS

explore

author：fashion 2025-08-28 08:40:19 - browse：337

ADAM FEUERSTEIN/STAT

CHICAGO — Corbus Pharmaceuticals is the second best-performing biotech stock this year, thanks to investor interest in an antibody-drug conjugate candidate, or ADC, called CRB-701 with the potential to be better tolerated than Padcev, an ADC treatment bladder cancer that Pfizer acquired as part of its $43 billion Seagen deal.

On Saturday, Corbus updated results from an early, dose-finding study of CRB-701, showing an overall response rate of 28% from 25 evaluable patients. Closer attention is being paid to the subset of 15 patients treated at three therapeutically active doses, where the overall response rate (all partial tumor shrinkage) was 40%. All of the responses were seen in bladder cancer (where Padcev is approved) and in cervical cancer.

The data, from a study conducted in China, were presented in a poster session at the annual meeting of the American Society of Clinical Oncology.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Fetal surgery at risk from Dobbs and new abortion restrictions

entertainment

WSS

CDC director unscathed in first congressional testimony

STAT Readout: Today's biotech news includes Sana and Amylyx

What don’t we know about an Alzheimer’s drug side effect?

Despite FDA concern, risk that CAR

How to pay for weight loss drugs and save Medicare

Rep. Raul Ruiz on the physician shortage and more

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

How one medical school became remarkably diverse

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Bright Health sells Medicare Advantage business to Molina

Female surgeons have lower rates of long

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Female surgeons have lower rates of long

After affirmative action ruling, medical educators look to 'holistic review'

Despite FDA concern, risk that CAR

George Santos makes 1st court appearance after pleading not guilty to 13 counts

What the Wegovy shortage looks like for doctors — and for patients

knowledge

STAT Readout Newsletter: Today in biotech, life science news

Despite FDA concern, risk that CAR

Eight reasons why you should get an updated Covid vaccine

Fetal surgery at risk from Dobbs and new abortion restrictions

There’s no way to know how good AI health technologies are

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

entertainment

hotspot

entertainment

Wikipedia